ChromoKey Phase 2 Study Demonstrates Promising Activity of Lenvatinib + Pembrolizumab in Metastatic Chromophobe #RenalCellCarcinoma. Presented by Ilya Tsimafeyeu, MD, PhD. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4jDD0GK #KidneyCancer #RCC @myESMO